Trial Information

Summary: A Phase IV Alzheimer's Disease Trial studying the effectiveness and safety of donepezil hydrochloride (Aricept) in the Hispanic population

Patients will be enrolled according to inclusion/exclusion criteria. Eligible patients will receive 5mg donepezil once daily for the first 6 weeks, after which time their dosage should be increased to 10mg per day. Patients and caregivers will return to the clinic for efficacy and safety assessments at weeks 6 and 12. A telephone contact will be conducted at week 8. Patients who complete the study will be offered an additional supply of Aricept for AD treatment based on the clinical judgement of the investigator.

Patient Inclusion Criteria

• Patients 50 years or older
• Hispanic male or female
• Have been diagnosed with Alzheimer's Disease

Patient Exclusion Criteria

• Patients with hypersensitivity to cholinesterase inhibitor

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.